- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02621593
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
Feasibility of Intense Pulsed Light (IPL) for Reducing Dry Eye Symptoms Caused by Meibomian Gland Dysfunction (MGD)
Study Overview
Detailed Description
The IPL module has FDA clearance (K142860) for a wide range of indications, including benign cavernous hemangiomas, benign venous malformations, telangiectasia, port-wine stains, pigmented lesions and erythema of rosacea. As shown by a retrospective study, in over 85% of the cases, using IPL in subjects with ocular rosacea also alleviated the symptoms of DED caused by MGD. No serious adverse events were recorded, suggesting that IPL therapy administered close to the ocular orbits is safe (provided that the eyes are shielded). However, the above mentioned study was retrospective. Therefore, additional evidence is needed in order to substantiate the hypothesis that alleviation of MGD symptom was facilitated by IPL treatments.
The aim of the current study is to assess the safety and efficacy of IPL treatment for reducing the symptoms of dry eye disease (DED) in subjects with MGD. The study hypothesis is that in a study population of subjects diagnosed with moderate to severe MGD, 4 sessions of IPL therapy with the M22 system, followed by expression of the MGs, will cause a significant increase in tear break-up time post-treatment, compared to pre-treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Gaster Eye Center
-
-
Texas
-
Austin, Texas, United States, 78746
- Dell Laser Consultants
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read, understand and sign an Informed Consent (IC) form
- 18-80 years of age
- Fitzpatrick skin type 1-4
- Able and willing to comply with the treatment/follow-up schedule and requirements
- At least 5 non-atrophied glands on each eye's lower eyelid
Current diagnosis of moderate to severe MGD in both eyes, including 2 of the following 5 criteria:
- Tear break-up time (TBUT) ≤ 10 seconds in both eyes;
- Meibomian gland (MG) score (using the Abbreviated MGD grading system for clinical trials) ≥ 11 in both eyes
- Corneal Fluorescein Staining (CFS) score (using the Baylor grading scheme) ≥ 10 in both eyes;
- Tear Osmolarity ≥ 310 milliosmol/L in both eyes, or a difference higher than 8 milliosmol/L between the two eyes
- SPEED ≥ 10
- Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nuvaring and partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.
Exclusion Criteria:
- Contact lens wearer within the past 1 month and throughout the study
- Recent ocular surgery or eyelid surgery within the past 6 months
- Neuro-paralysis in the planned treatment area within the past 6 months
- Other uncontrolled eye disorders affecting the ocular surface
- Current use of punctal plugs
- Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area
- Uncontrolled infections or uncontrolled immunosuppressive diseases
- Subjects who have undergone laser in situ keratomileusis (LASIK) surgery within the past 6 months
- Diseases in the planned treatment area that could be stimulated by light at 560 nm to 1200 nm (e.g., Herpes simplex 1 and 2, Systemic Lupus erythematosus, porphyria)
- Use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, such as Isotretinoin, Tetracycline, or St. John's Wort
- Over exposure to sun within the past 4 weeks, in the judgment of the treating physician
- Pregnancy and nursing
- Administration of prescription eye drops for dry eye within the past 48 hours, excluding artificial tears
- Radiation therapy to the head or neck within the past year, or planned radiation therapy within 8 weeks after completion of all IPL treatments
- Treatment with chemotherapeutic agent within the past 8 weeks, or planned chemotherapy within 8 weeks after completion of all IPL treatments
- New topical treatments within the area to be treated, or oral therapies within the past 3 months, except over-the-counter acetaminophen-based analgesics (such as Extra Strength Tylenol®) for pain management after study treatment
- Change in dosage of any systemic medication within the past 3 months
- Anticipated relocation or extensive travel outside of the local study area preventing compliance with follow-up within the next 16 weeks
- Any condition revealed during the eligibility screening process whereby the physician deems the subject inappropriate for this study
- Declared legally blind in one eye
- History of migraines, seizures or epilepsy
- IPL treatment within the past 12 months
- Lipiflow treatment, or any equivalent treatment, within the past 12 months
- Expression of the meibomian glands within the past 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment of dry eye secondary to MGD
Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
|
The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions.
The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm.
The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tear Break-up time in seconds, using the standard Fluorescein staining method
Time Frame: from Baseline to 3 weeks after the 3rd treatment and 3 weeks after the fourth/final treatment
|
The number of seconds that elapse between the last blink of the eye to the appearance of the first dry spot in the tear film
|
from Baseline to 3 weeks after the 3rd treatment and 3 weeks after the fourth/final treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Corneal fluorescein staining score, using the Baylor Scheme
Time Frame: from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
The cornea will be viewed and logically divided to 5 zones: central, superior, inferior, temporal and nasal.
In each of the 5 zones, grading will be as follows: 0 dots = 0; 1-5 dots = 1; 16-30 dots = 3; > 30 dots = 4; One point will be added to the score in case of 1 area of confluent staining.
Two points will be added to the score in case of two or more areas of confluent staining.
The total score is the sum of scores in the 5 zones
|
from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
Meibomian gland score, using the "Abbreviated MGD grading system for clinical trials"
Time Frame: from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
|
from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
Subjective symptoms, using the SPEED questionnaire
Time Frame: from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
SPEED is a validated questionnaire for quantifying the subjective symptoms of DED. The questionnaire will be filled by the study investigator (with questions answered by the subject). In 4 symptoms are evaluated: (1) dryness, grittiness or scratchiness; (2) Soreness or Irritation; (3) Burning or watering; and (4) Eye fatigue. Two types of questions are asked about these symptoms: frequency and severity. In the Frequency questions, subjects evaluate the 4 symptoms above on a 0-3 scale: 0 = Never; 1 = Sometimes; 2 = Often; and 3 = All the time. In the Severity questions, subjects evaluate the 4 symptoms above on a 0-4 scale: 0 = No problems; 1 = Tolerable (not perfect but not uncomfortable); 2 = Uncomfortable (irritating but does not interfere with my day); 3 = Bothersome (irritating and interferes with my day); and (4) Intolerable (unable to perform my daily tasks). The total score is the sum of the Frequency answers and the Severity answers. |
from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
Tear Osmolarity in milliosmol/liter, using a lab-on-a-chip system to simultaneously collect and analyze the electrical impedance of a tear sample
Time Frame: from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
In this current study, tear osmolarity will be measured using a lab-on-a-chip system to simultaneously collect and analyze the electrical impedance of a tear sample (TearLab, San Diego, CA, USA).
A small tear sample of 50 nL will be collected from the lower meniscus, using a disposable test chip by passive capillary action, and transferred to the device.
Several seconds after the transfer, readings will be given in milliOsmol/L
|
from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
Lipid Layer Thickness in nanometers, using an interferometer
Time Frame: from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
lipid layer thickness will be measured using an interferometer.
In interferometry, when white light is projected over the cornea, a color interference pattern is produced due to specular reflection at the lipid-aqueous interface.
The reflected colors from the tear film are captured on a high-resolution video.
Each recorded pixel is analyzed, and compared with a color progression table.
The output is expressed as interference color units (ICUS), which correlate with lipid layer thickness
|
from Baseline to 3 weeks after the 3rd treatment; 3 weeks after the fourth/final treatment; 6 weeks after the final treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-related adverse events and serious adverse events
Time Frame: 1 day after baseline; 1 week after baseline ; 3 weeks after baseline (Tx2); 6 weeks after baseline (Tx3); 9 weeks after baseline (Tx4/FU1); 12 weeks after baseline (FU2); and 15 weeks after baseline (FU3)
|
Evaluation will be done by subject's report and/or by the physician's judgment
|
1 day after baseline; 1 week after baseline ; 3 weeks after baseline (Tx2); 6 weeks after baseline (Tx3); 9 weeks after baseline (Tx4/FU1); 12 weeks after baseline (FU2); and 15 weeks after baseline (FU3)
|
immediate/short term skin response
Time Frame: At Baseline (Tx1); 3 weeks after baseline (Tx2); 6 weeks after baseline (Tx3); and 9 weeks after baseline (Tx4/FU1)
|
Evaluation will be done by the physician judgment
|
At Baseline (Tx1); 3 weeks after baseline (Tx2); 6 weeks after baseline (Tx3); and 9 weeks after baseline (Tx4/FU1)
|
Subjective level of pain/discomfort.
Time Frame: At Baseline (Tx1); 3 weeks after baseline (Tx2); 6 weeks after baseline (Tx3); and 9 weeks after baseline (Tx4/FU1)
|
Evaluation will be done by the subject, using a Visual Analog Scale (VAS)
|
At Baseline (Tx1); 3 weeks after baseline (Tx2); 6 weeks after baseline (Tx3); and 9 weeks after baseline (Tx4/FU1)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven Dell, MD, Medical Director, Dell LAser Consultants
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LUM-VBU-M22-15-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndromes
-
Singapore National Eye CentreCompleted
-
Singapore National Eye CentreCompleted
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
OptovueCompleted
-
Horus PharmaEurofins Dermscan PharmascanRecruitingDry EyeFrance, Poland, Spain, United Kingdom
Clinical Trials on M22-IPL
-
Second Affiliated Hospital, School of Medicine,...RecruitingErythematotelangiectatic RosaceaChina
-
Lumenis Be Ltd.CompletedImprovement of Wrinkles/Elastosis and/or PigmentationUnited States, Germany
-
Goldman, Butterwick, Fitzpatrick and GroffNot yet recruitingKeratosis Pilaris
-
Université de SherbrookeRecruitingDry Eye | Contact Lens ComplicationCanada
-
Lumenis Be Ltd.CompletedImprovement of Wrinkles/Elastosis as Well as General Skin ToneUnited States
-
He Eye HospitalNot yet recruiting
-
Aston UniversityRecruitingDry Eye Syndromes | Meibomian Gland DysfunctionUnited Kingdom
-
First Affiliated Hospital of Harbin Medical UniversityCompleted
-
BioLeaders CorporationCompleted